EnWave Signs Technology Evaluation and License Option Agreement with Swiss Cannabis Selection AG, Announces Significant Evaluation Results

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today that it has entered into a Technology Evaluation and License Option Agreement (the “Agreement”) with Swiss Cannabis Selection AG (“SCS”), a Switzerland based medical cannabis company focused on the cultivation, development and production of cannabis and cannabis products for medical purposes. SCS is collaborating with Schibano Pharma AG (“Schibano”), a Switzerland based phytopharmaceutical company specializing in cannabinoid derived active pharmaceutical ingredients, medicinal products and wellness solutions, on the evaluation of EnWave’s proprietary Radiant Energy Vacuum (“REV™”) dehydration technology.

Under the terms of the Agreement, SCS, in collaboration with Schibano, will conduct a comprehensive evaluation of EnWave’s proprietary Radiant Energy Vacuum (“REV™”) dehydration technology for potential application across a range of cannabinoid and botanical products. Upon successful completion of the evaluation program, SCS will have the option to enter into a commercial license agreement granting certain rights to deploy REV™ technology within agreed-upon markets and applications.

The Agreement follows a series of recent commercial-scale evaluations of REV™ technology that demonstrated the ability to accelerate drying timelines while maintaining key product quality characteristics. Independent testing conducted across multiple cannabis cultivars showed no statistically significant differences in sensory quality compared to conventionally dried control samples, no meaningful impact on cannabinoid potency, no material change in total yeast and mold counts, and generally stable terpene profiles. The evaluations also demonstrated the potential to reduce overall drying time by approximately two to five days, creating opportunities for increased production throughput and reduced dry-room occupancy.

SCS is collaborating with Schibano on the evaluation program. SCS operates an advanced indoor cannabis cultivation facility and focuses on the production of high quality medical cannabis under ecological standards and GACP compliant practices. Schibano operates a vertically integrated “Seed-to-Pharma” platform encompassing genetics development, cultivation, extraction, active pharmaceutical ingredient manufacturing and finished product production. It maintains pharmaceutical-quality manufacturing standards and serves customers across international markets. Together, the companies bring complementary expertise spanning cannabis cultivation, pharmaceutical development and cannabinoid product manufacturing.

The evaluation will focus on assessing REV™ technology’s ability to process cannabinoid and botanical materials efficiently while preserving critical quality attributes and meeting the operational and regulatory requirements of SCS and Schibano. Evaluation activities are expected to commence in the coming months.

About Swiss Cannabis Selection AG

SCS Swiss Cannabis Selection AG is a Switzerland based medical cannabis company specializing in the cultivation, development and production of cannabis and cannabis products for medical purposes. The company operates an advanced indoor cultivation facility in the St. Gallen Rhine Valley and produces high quality Swiss cannabis under ecological standards and GACP compliant practices. Through its cultivation expertise and focus on quality, SCS supports the development of cannabis products for medicinal and regulated markets. SCS’s advanced cultivation capabilities and commitment to producing high quality medical cannabis position the company among the emerging innovators helping shape Switzerland’s rapidly evolving medical cannabis sector. For more information on SCS, please visit https://cannabis-selection.ch/.

About Schibano Pharma AG

Schibano Pharma AG is a Switzerland-based life sciences and phytopharmaceutical company specializing in cannabinoid-derived active pharmaceutical ingredients, medicinal products and medical wellness solutions. Through its proprietary “Seed-to-Pharma” platform, the company integrates research and development, genetics, cultivation, pharmaceutical manufacturing and regulatory expertise to deliver high-quality cannabinoid products to pharmaceutical, clinical and commercial markets. Schibano Pharma’s GMP-certified operations and longstanding focus on cannabinoid innovation position the company among the early pioneers in the development of pharmaceutical-grade cannabinoid solutions in Europe. For more information on Schibano, please visit https://schibano-swiss-pharma.com/en/.

Acerca de EnWave

EnWave es líder mundial en innovación y aplicación de la deshidratación por microondas al vacío. Desde su sede en Delta (Columbia Británica), EnWave ha desarrollado una sólida cartera de propiedad intelectual, ha perfeccionado su tecnología Radiant Energy Vacuum (REV™) y ha transformado una idea innovadora en una solución de secado probada, consistente y escalable para las industrias alimentaria, farmacéutica y del cannabis que supera ampliamente a los métodos de secado tradicionales en eficiencia, capacidad, calidad del producto y coste.

With more than fifty partners spanning twenty-four countries and five continents, EnWave’s licensed partners are creating profitable, never-before-seen snacks and ingredients, improving the quality and consistency of their existing offerings, running leaner and getting to market faster with the company’s patented technology, licensed machinery, and expert guidance.

La estrategia de EnWave consiste en firmar licencias comerciales sujetas a derechos de autor con productores de alimentos que deseen secar mejor, más rápido y de forma más económica que la liofilización, el secado en bastidor y el secado al aire, y disfrutar de las siguientes ventajas: producir productos nuevos e interesantes, alcanzar niveles óptimos de humedad hasta siete veces más rápido y mejorar el sabor, la textura, el color y el valor nutritivo del producto.

Learn more at EnWave.net

Corporación EnWave

Sr. Brent Charleton, CFA

Presidente y Consejero Delegado

Para más información:

Brent Charleton, CFA, Presidente y Director General, +1 (778) 378-9616
Correo electrónico: bcharleton@enwave.net      

Dylan Murray, CPA, CA, CFO al +1 (778) 870-0729
Correo electrónico: dmurray@enwave.net  

Safe Harbour para declaraciones de información prospectiva: Este comunicado de prensa puede contener información prospectiva basada en las expectativas, estimaciones y proyecciones de la dirección. Todas las declaraciones que se refieran a expectativas o proyecciones sobre el futuro, incluidas las declaraciones sobre la estrategia de crecimiento de la empresa, el desarrollo de productos, la posición en el mercado, los gastos previstos y las sinergias esperadas tras el cierre son declaraciones prospectivas. No se garantiza la exactitud de todas las afirmaciones de terceros a las que se hace referencia en este comunicado. No se garantiza la exactitud de todas las referencias de terceros a información de mercado contenidas en este comunicado, ya que la empresa no ha llevado a cabo la investigación primaria original. Estas afirmaciones no constituyen una garantía de resultados futuros e implican una serie de riesgos, incertidumbres y suposiciones. Aunque la empresa ha intentado identificar los factores importantes que podrían hacer que los resultados reales difirieran materialmente, puede haber otros factores que hagan que los resultados no sean los previstos, estimados o deseados. No puede garantizarse que tales afirmaciones resulten exactas, ya que los resultados reales y los acontecimientos futuros podrían diferir sustancialmente de los previstos en dichas afirmaciones. Por consiguiente, los lectores no deben depositar una confianza indebida en las afirmaciones de carácter prospectivo.

Ni la TSX Venture Exchange ni su Proveedor de Servicios de Regulación (según se define este término en las políticas de la TSX Venture Exchange) aceptan responsabilidad alguna por la adecuación o exactitud de este comunicado.